Real-world outcomes for a complete nationwide cohort of more than 3200 teriflunomide-treated multiple sclerosis patients in The Danish Multiple Sclerosis Registry.

<h4>Objective</h4>Teriflunomide is a once-daily, oral disease-modifying therapy (DMT) for relapsing forms of multiple sclerosis (MS). We studied clinical outcomes in a real-world setting involving a population-based large cohort of unselected patients enrolled in The Danish Multiple Scle...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Viktoria Papp, Mathias Due Buron, Volkert Siersma, Peter Vestergaard Rasmussen, Zsolt Illes, Matthias Kant, Claudia Hilt, Zsolt Mezei, Homayoun Roshanisefat, Tobias Sejbæk, Arkadiusz Weglewski, Janneke van Wingerden, Svend Sparre Geertsen, Stephan Bramow, Finn Sellebjerg, Melinda Magyari
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/4c38c13ec9ce425b87933408ba9724f9
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Sea el primero en dejar un comentario!

Real-world outcomes for a complete nationwide cohort of more than 3200 teriflunomide-treated multiple sclerosis patients in The Danish Multiple Sclerosis Registry.

Ejemplares similares